Valneva (VALN) announced that the Brazilian Health Regulatory Agency has granted marketing authorization to its single-dose vaccine Ixchiq for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The decision marks the world’s first approval of a chikungunya vaccine in an endemic country, the company said in a statement. ANVISA continues to review VLA1555, the chikungunya vaccine candidate which, if approved, will be locally manufactured and distributed by Instituto Butantan pursuant to its collaboration with Valneva. Potential approval is anticipated in mid-2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Positive Outlook for Valneva Driven by Promising Vaccine Pipeline and Strategic Developments
- Valneva and LimmaTech Initiate Phase 2 Study of Shigella Vaccine
- Valneva’s Chikungunya Vaccine Gains EU Approval for Adolescents
- Valneva granted EC marketing authorization for Ixchiq vaccine
- Valneva’s Strategic Advancements and Promising Projections Drive Buy Rating with $17 Target